Confirmed 6-Month Disability Improvement and Worsening Correlate with Long-term Disability Outcomes in Alemtuzumab-Treated Patients with Multiple Sclerosis: Post Hoc Analysis of the CARE-MS Studies
Author:
Funder
Sanofi
Pharmaceuticals Bayer
Publisher
Springer Science and Business Media LLC
Subject
Neurology (clinical),Neurology
Link
https://link.springer.com/content/pdf/10.1007/s40120-021-00262-3.pdf
Reference41 articles.
1. Conradsson D, Ytterberg C, von Koch L, Johansson S. Changes in disability in people with multiple sclerosis: a 10-year prospective study. J Neurol. 2018;265(1):119–26.
2. Sutliff MH. Contribution of impaired mobility to patient burden in multiple sclerosis. Curr Med Res Opin. 2010;26(1):109–19.
3. Chalmer TA, Baggesen LM, Norgaard M, et al. Early versus later treatment start in multiple sclerosis: a register-based cohort study. Eur J Neurol. 2018;25(10):1262-e110.
4. Stankiewicz JM, Weiner HL. An argument for broad use of high efficacy treatments in early multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2020;7(1):e636.
5. Harding K, Williams O, Willis M, et al. Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis. JAMA Neurol. 2019;76(5):536–41.
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The Faces of “Too Late”—A Surprisingly Progressive Cohort of “Stable” Relapsing Remitting Multiple Sclerosis Patients;Medicina;2024-08-26
2. Long-term follow up of alemtuzumab-treated patients: a retrospective study in a Belgian tertiary care center;Acta Neurologica Belgica;2024-04-15
3. Deep Survival Analysis in Multiple Sclerosis;Predictive Intelligence in Medicine;2023
4. The Place of Immune Reconstitution Therapy in the Management of Relapsing Multiple Sclerosis in France: An Expert Consensus;Neurology and Therapy;2022-12-24
5. Alemtuzumabterápiával kezelt sclerosis multiplexes betegek követéses vizsgálata a szegedi Sclerosis Multiplex Centrumban;Ideggyógyászati szemle;2022
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3